Diroximel Fumarate

CAS 1577222-14-0

General Information

Diroximel fumarate, also known as ALKS-8700, is in Phase III clinical trials for the treatment of relapsing remitting multiple sclerosis, which is the most common form of multiple sclerosis (MS). Relapsing remitting MS is characterized by episodes of worsening neurologic functioning followed by partial or complete recovery periods free of disease progression.

About the API

Systematic name 4-O-[2-(2,5-dioxopyrrolidin-1-yl)ethyl] 1-O-methyl (E)-but-2-enedioate
Trade name(s) (Still pending)
Technology Synthetic
Molecular Formula C11H13NO6 Molecular Weight
Physical properties Solid powder
Therapeutic category Immunology
Available formulations Oral Solid
Regulations US DMF Flag US DMF